More than 12,000 hematology professionals from around the world met together in Amsterdam, The Netherlands for the 24th European Hematology Association (EHA) Congress.
This has been the largest EHA Congress ever recorded with a growth of more than a thousand attendees from last year.
Once again, our CML patient advocates team has been participating in this important meeting for leukemia patients as well as for the patient advocacy community.
Our co-founders Jan Geissler, Giora Sharf and Jana Pelouchova as well as our Chair Sarunas Narbutas and several Steering Committee members and CML CAB members as Zack Pemberton-Whiteley or Felice Bombaci, plus our staff members, have been attending and actively participating in many sessions of the Congress.
Know more about what happened at #EHA24 on CML:
With the participation of more than 20 Chronic Myeloid Leukemia patient advocates, the extensive congress program included over 400 sessions of invited presentations, abstracts and sponsored sessions.
The EHA-Patient Joint Policy Symposium has included five sessions, mixed panels of hematologists, patient advocates, industry representatives and regulators discussing really hot topics for the Hematology patient advocacy community.
Our CML patient advocates Cornelia Borowczak, a CML-CAB as well as a member of the German organisation Elternverein für Kinder mit CML e.V. and Toni Montserrat, member of the LMC Pacientes group in Spain, were actively participating at the EHA Congress and providing us with detailed feedback of many interesting sessions for the CML patient advocates.
Summary
- The Capacity Building.
- The EHA-Patient Joint Policy Symposium
- EHA sessions
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
- European Hematology Association Congress 2019
Chronic Myeloid Leukemia
also called: Chronic Myelogeneous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
Hematologist
A physician who has specialized in blood diseases, including leukemia ("heme" means "blood" in Greek language)
Chronic
Long-lasting, slowly developping
CML
Chronic Myeloid Leukemia, also called Chronic Myelogenous Leukemia
A chronic disease of the blood and bone marrow that results from a transformation of a stem cell.
CHR
Abbreviation for Complete Hematologic Response. The blood cell count has returned to normal, and tests don’t show any immature white blood cells. Also, the spleen has returned to a normal size if it was enlarged.